Baxter International Files 8-K/A Amendment
Ticker: BAX · Form: 8-K/A · Filed: Feb 6, 2025 · CIK: 10456
Sentiment: neutral
Topics: amendment, regulatory-filing, disclosure
Related Tickers: BAX
TL;DR
Baxter filed an 8-K/A amendment, likely housekeeping. No major news.
AI Summary
Baxter International Inc. filed an amendment (8-K/A) on February 6, 2025, related to events reported as of January 31, 2025. This filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits, with no specific new financial figures or material events detailed in the provided text.
Why It Matters
This filing indicates an update or correction to a previous report, suggesting ongoing regulatory compliance and transparency from Baxter International Inc.
Risk Assessment
Risk Level: low — The filing is an amendment to a previous report, not a disclosure of new material negative events.
Key Players & Entities
- BAXTER INTERNATIONAL INC (company) — Registrant
- February 6, 2025 (date) — Filing Date
- January 31, 2025 (date) — Report Date
- 0001628280-25-004275 (filing_id) — Accession Number
FAQ
What is the purpose of this 8-K/A filing?
This 8-K/A filing is an amendment to a previous report, primarily concerning Regulation FD Disclosure and Financial Statements and Exhibits, as of January 31, 2025.
When was this amendment filed?
The amendment was filed on February 6, 2025.
What is the accession number for this filing?
The accession number for this filing is 0001628280-25-004275.
What is the principal business of Baxter International Inc.?
Baxter International Inc. is in the business of Surgical & Medical Instruments & Apparatus, with the SIC code 3841.
Does this filing disclose any new financial results?
The provided text does not detail any new specific financial results or figures; it indicates an amendment to existing disclosures.
Filing Stats: 877 words · 4 min read · ~3 pages · Grade level 12.1 · Accepted 2025-02-06 16:48:07
Key Financial Figures
- $1.00 — ange on which registered Common Stock, $1.00 par value BAX (NYSE) New York Stock Exc
- $3.80 billion — Sale for an aggregate purchase price of $3.80 billion in cash, subject to certain closing cas
- $3.71 billion — ed), the Company received approximately $3.71 billion in cash with the net after tax proceeds
- $3.4 billion — currently estimated to be approximately $3.4 billion. The information in Item 7.01 to this
Filing Documents
- bax-20250131.htm (8-K/A) — 32KB
- bax-2025013125xex991.htm (EX-99.1) — 311KB
- 0001628280-25-004275.txt ( ) — 555KB
- bax-20250131.xsd (EX-101.SCH) — 4KB
- bax-20250131_def.xml (EX-101.DEF) — 19KB
- bax-20250131_lab.xml (EX-101.LAB) — 35KB
- bax-20250131_pre.xml (EX-101.PRE) — 20KB
- bax-20250131_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On February 6, 2025, the Company announced that it completed the Vantive Sale for an aggregate purchase price of $3.80 billion in cash, subject to certain closing cash, working capital and debt adjustments. After giving effect to the adjustment mechanisms in the related Equity Purchase Agreement (as amended), the Company received approximately $3.71 billion in cash with the net after tax proceeds currently estimated to be approximately $3.4 billion. The information in Item 7.01 to this Current Report on Form 8-K, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except in the event that the Company expressly states that such information is to be considered filed under the Exchange Act or incorporates it by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (b) Pro forma financial information The following unaudited pro forma financial information of the Company is filed as Exhibit 99.1 to this Amendment No. 1 to the Original Form 8-K and is incorporated herein by reference: Unaudited Pro Forma Condensed Consolidated Balance Sheet as of September 30, 2024 Unaudited Pro Forma Condensed Consolidated Statement of Income (Loss) for the Nine Months Ended September 30, 2024 Unaudited Pro Forma Condensed Consolidated Statement of Income (Loss) for the Years Ended December 31, 2023, 2022 and 2021 Notes to the Unaudited Pro Forma Consolidated Financial Information (d) Exhibits. Exhibit Number Description 99.1 Unaudited Pro Forma Condensed Consolidated Financial Information 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: February 6, 2025 BAXTER INTERNATIONAL INC. By: /s/ Joel T. Grade Name: Joel T. Grade Title: Executive Vice President, Chief Financial Officer and Interim Chief Accounting Officer